Miller Anestesia

1. Cohen MM, Duncan PG, Tate RB: Does anesthesia

contribute to operative mortality? JAMA 260:2859–

2863, 1988.

1a. Kay B, Rolly G: I.C.I. 35868—The effect of a change

of formulation on the incidence of pain after intra-

venous injection. Acta Anaesthesiol Belg 28(4)317–

322, 1977.

2. James R, Glen JB: Synthesis, biological evaluation,

and preliminary structure-activity considerations

of a series of alkylphenols as intravenous anesthetic

agents. J Med Chem 23:1350–1357, 1980.

3. Gan TJ: Pharmacokinetic and pharmacodynamic

characteristics of medications used for moderate

sedation. Clin Pharmacokinet 45:855–869, 2006.

4. Simons P, Cockshott I, Douglas E: Blood concentra-

tions, metabolism and elimination after a subanes-

thetic intravenous dose of (14)C-propofol

(Diprivan) to male volunteers. Postgrad Med J

61:64, 1985.

5. Veroli P, O’Kelly B, Bertrand F, et al: Extrahepatic

metabolism of propofol in man during the anhepa-

tic phase of orthotopic liver transplantation. Br J

Anaesth 68:183–186, 1992.

6. Takizawa D, Hiraoka H, Goto F, et al: Human

kidneys play an important role in the elimination

of propofol. Anesthesiology 102:327–330, 2005.

7. Hiraoka H, Yamamoto K, Miyoshi S, et al: Kidneys

contribute to the extrahepatic clearance of propofol

in humans, but not lungs and brain. Br J Clin Phar-

macol 60:176–182, 2005.

8. Raoof AA, van Obbergh LJ, de Ville de Goyet J,

Verbeeck RK: Extrahepatic glucuronidation of pro-

pofol in man: Possible contribution of gut wall and

kidney. Eur J Clin Pharmacol 50:91–96, 1996.

9. Kuipers JA, Boer F, OliemanW, et al: First-pass lung

uptake and pulmonary clearance of propofol:

Assessment with a recirculatory indocyanine green

pharmacokinetic model. Anesthesiology 91:1780–

1787, 1999.

10. Dawidowicz AL, Fornal E, Mardarowicz M, Fija-

lkowska A: The role of human lungs in the biotrans-

formation of propofol. Anesthesiology 93:992–997,

2000.

11. Chen TL, Ueng TH, Chen SH, et al: Human cyto-

chrome P450 mono-oxygenase system is suppres-

sed by propofol. Br J Anaesth 74:558–562, 1995.

12. Fechner J, Ihmsen H, Hatterscheid D, et al: Phar-

macokinetics and clinical pharmacodynamics of

the new propofol prodrug GPI 15715 in volunteers.

Anesthesiology 99:303–313, 2003.

13. Kay NH, Sear JW, Uppington J, et al: Disposition of

propofol in patients undergoing surgery: A compa-

rison in men and women. Br J Anaesth 58:1075–

1079, 1986.

14. Gepts E, Camu F, Cockshott ID, Douglas EJ: Dispo-

sition of propofol administered as constant rate

intravenous infusions in humans. Anesth Analg

66:1256–1263, 1987.

15. Schuttler J, Stoeckel H, Schwilden H: Pharmacoki-

netic and pharmacodynamic modeling of propofol

(Diprivan) in volunteers and surgical patients. Post-

grad Med J 61:53, 1985.

16. Hughes MA, Glass PS, Jacobs JR: Context-sensitive

half-time in multicompartment pharmacokinetic

models for intravenous anesthetic drugs. Anesthe-

siology 76:334–341, 1992.

17. Gray PA, Park GR, Cockshott ID, et al: Propofol

metabolism in man during the anhepatic and reper-

fusion phases of liver transplantation. Xenobiotica

22:105–114, 1992.

18. Dyck J, Varvel J, Hung O: The pharmacokinetics of

propofol vs. age. Anesthesiology 75:A315, 1991.

19. Kazama T, Ikeda K, Morita K, et al: Comparison of

the effect-site k(eO)s of propofol for blood pressure

and EEG bispectral index in elderly and younger

patients. Anesthesiology 90:1517–1527, 1999.

20. Schnider TW, Minto CF, Shafer SL, et al: The

influence of age on propofol pharmacodynamics.

Anesthesiology 90:1502–1516, 1999.

21. Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo

WS: Pharmacokinetics of propofol (diprivan) in

elderly patients. Br J Anaesth 60:146–150, 1988.

22. Shafer A, Doze VA, Shafer SL, White PF: Pharma-

cokinetics and pharmacodynamics of propofol

infusions during general anesthesia. Anesthesio-

logy 69:348–356, 1988.

23. Morcos W, Payne J: The induction of anaesthesia

with propofol (Diprivan) compared in normal and

renal failure patients. Postgrad Med J 61:62–63,

1985.

24. Leslie K, Sessler DI, Bjorksten AR, Moayeri A: Mild

hypothermia alters propofol pharmacokinetics and

increases the duration of action of atracurium.

Anesth Analg 80:1007–1014, 1995.

25. Upton RN, Ludbrook GL, Grant C, Martinez AM:

Cardiac output is a determinant of the initial con-

centrations of propofol after short-infusion admi-

nistration. Anesth Analg 89:545–552, 1999.

26. Kurita T, Morita K, Kazama T, Sato S: Influence of

cardiac output on plasma propofol concentrations

during constant infusion in swine. Anesthesiology

96:1498–1503, 2002.

27. Kazama T, Kurita T, Morita K, et al: Influence of

hemorrhage on propofol pseudo-steady state con-

centration. Anesthesiology 97:1156–1161, 2002.

28. Allegaert K, Peeters MY, Verbesselt R, et al: Inter-

individual variability in propofol pharmacokinetics

in preterm and term neonates. Br J Anaesth 99:864–

870, 2007.

29. Bailey JM, Mora CT, Shafer SL: Pharmacokinetics

of propofol in adult patients undergoing coronary

revascularization. The Multicenter Study of Perio-

perative Ischemia Research Group. Anesthesiology

84:1288–1297, 1996.

30. Marsh B,White M, Morton N, Kenny GN: Pharma-

cokinetic model driven infusion of propofol in chil-

dren. Br J Anaesth 67:41–48, 1991.

31. Kataria BK,Ved SA, Nicodemus HF, et al: The phar-

macokinetics of propofol in children using three

different data analysis approaches. Anesthesiology

80:104–122, 1994.

32. Murat I, Billard V,Vernois J, et al: Pharmacokinetics

of propofol after a single dose in children aged 1-3

years with minor burns: Comparison of three data

analysis approaches. Anesthesiology 84:526–532,

1996.

33. Servin F, Desmonts JM, Farinotti R, et al: [Pharma-

cokinetics of the continuous infusion of propofol in

the cirrhotic patient: Preliminary results]. Ann Fr

Anesth Reanim 6:228–229, 1987.

34. Benoni G, Cuzzolin L, Gilli E: Pharmacokinetics of

propofol: Influence of fentanyl administration. Eur

J Anaesthesiol 183:1457, 1990.

35. Pavlin DJ, Coda B, Shen DD, et al: Effects of com-

bining propofol and alfentanil on ventilation, anal-

gesia, sedation, and emesis in human volunteers.

Anesthesiology 84:23–37, 1996.

36. Gill SS, Wright EM, Reilly CS: Pharmacokinetic

interaction of propofol and fentanyl: Single bolus

injection study. Br J Anaesth 65:760–765, 1990.

37. Matot I, Neely CF, Katz RY, Marshall BE: Fentanyl

and propofol uptake by the lung: Effect of time

between injections. Acta Anaesthesiol Scand

38:711–715, 1994.

38. Janicki PK, James MF, Erskine WA: Propofol inhi-

bits enzymatic degradation of alfentanil and sufen-

tanil by isolated liver microsomes in vitro. Br J

Anaesth 68:311–312, 1992.

39. Gibiansky E, Struys MM, Gibiansky L, et al:

AQUAVAN injection, a water-soluble prodrug of

propofol, as a bolus injection: A phase I dose-esca-

lation comparison with DIPRIVAN (part 1): Phar-

macokinetics. Anesthesiology 103:718–729, 2005.

40. Struys MM, Vanluchene AL, Gibiansky E, et al:

AQUAVAN injection, a water-soluble prodrug of

propofol, as a bolus injection: A phase I dose-esca-

lation comparison with DIPRIVAN (part 2): Phar-

macodynamics

and

safety.

Anesthesiology

103:730–743, 2005.

41. Krasowski MD, Nishikawa K, Nikolaeva N, et al:

Methionine 286 in transmembrane domain 3 of the

GABAA receptor beta subunit controls a binding

cavity for propofol and other alkylphenol general

anesthetics.

Neuropharmacology

41:952–964,

2001.

42. Jurd R, Arras M, Lambert S, Drexler B: General

anesthetic actions in vivo strongly attenuated by a

point mutation in the GABA

receptor beta-3

subunit. FASEB J, 2002.

43. Lam DW, Reynolds JN: Modulatory and direct

effects of propofol on recombinant GABA

recep-

tors expressed in xenopus oocytes: Influence of

alpha- and gamma2-subunits. Brain Res 784:179–

187, 1998.

44. Kikuchi T, Wang Y, Sato K, Okumura F: In vivo

effects of propofol on acetylcholine release from the

frontal cortex, hippocampus and striatum studied

by intracerebral microdialysis in freely moving rats.

Br J Anaesth 80:644–648, 1998.

45. Kushikata T, Hirota K, Yoshida H, et al: Alpha-2

adrenoceptor activity affects propofol-induced

sleep time. Anesth Analg 94:1201–1206, 2002.

46. Lingamaneni R, Birch ML, Hemmings HC Jr:

Widespread inhibition of sodium channel-depen-

dent glutamate release from isolated nerve termi-

nals by isoflurane and propofol. Anesthesiology

95:1460–1466, 2001.

47. Antognini J, Wang X, Piercy M, Carstens E: Propo-

fol directly depresses lumbar dorsal horn neuronal

responses to noxious stimulation in goats. Can J

Anaesth 47:273–279, 2000.

48. Dong XP, Xu TL: The actions of propofol on

gamma-aminobutyric acid-A and glycine receptors

in acutely dissociated spinal dorsal horn neurons of

the rat. Anesth Analg 95:907–914, 2002.

49. Tonner PH, Poppers DM, Miller KW: The general

anesthetic potency of propofol and its dependence

on hydrostatic pressure. Anesthesiology 77:926–

931, 1992.

50. Pain L, Gobaille S, Schleef C, et al: In vivo dopamine

measurements in the nucleus accumbens after

nonanesthetic and anesthetic doses of propofol in

rats. Anesth Analg 95:915–919, 2002.

51. Cechetto DF, Diab T, Gibson CJ, Gelb AW: The

effects of propofol in the area postrema of rats.

Anesth Analg 92:934–942, 2001.

52. Adam HK, Kay B, Douglas EJ: Blood disoprofol

levels in anesthetised patients: Correlation of con-

centrations after single or repeated doses with hyp-

notic activity. Anaesthesia 37:536–540, 1982.

Bibliografía

Anestésicos intravenosos

525

Sección II

Farmacología y anestesia